SCHEDULE 13G/A: Paradigm BioCapital Entities Divest Entire Stake in Kura Oncology, Inc.

Paradigm BioCapital Advisors LP and its affiliated entities have reported the complete divestiture of their beneficial ownership in Kura Oncology, Inc. as of December 31, 2024.

Summary

• This Schedule 13G Amendment No. 2 filing reports a change in beneficial ownership of Common Stock of Kura Oncology, Inc. (Issuer).
• The Reporting Persons, including Paradigm BioCapital Advisors LP, Paradigm BioCapital Advisors GP LLC, Senai Asefaw, M.D., and Paradigm BioCapital International Fund Ltd., no longer beneficially own any Common Stock of the Issuer.
• As of the event date of December 31, 2024, the aggregate amount beneficially owned by each Reporting Person is 0.00 shares, representing 0.0% of the class.
• This indicates a complete divestment of their holdings in Kura Oncology, Inc.

Sentiment

Score: 5

Explanation: The document is a factual regulatory filing reporting a complete divestment of shares, without providing any positive or negative commentary on the issuer's performance or outlook.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding Kura Oncology, Inc.'s future performance or operations.

Industry Context

This filing is a standard regulatory disclosure reporting a change in an institutional investor's stake in a publicly traded biotechnology company. It does not provide broader industry trends or competitive analysis.

Stakeholder Impact

• Shareholders of Kura Oncology, Inc. may note the complete exit of Paradigm BioCapital entities as an institutional investor.

Key Dates

Keywords

Kura Oncology, Paradigm BioCapital, SEC filing, Schedule 13G, beneficial ownership, common stock, divestment, institutional investor